In theory, this should offer an improved way of delivering doxorubicin.
CytRx is planning to enter the phase II trial for this drug in the second-half of 2011:
http://www.cytrx.com/inno_206.html
The clinicaltrial.gov website is still listing the phase I trial as open but I am not sure it is up to date:
http://www.clinicaltrials.gov/ct2/show/NCT01337505?intr=%22INNO-206%22&rank=1